A comprehensive approach to fragility fractures

Journal of Orthopaedic Trauma

Volumn 25, Issue 9, 2011, Pages 566-573

  Rebolledo, Brian J ^a   Unnanuntana, Aasis ^b,c   Lane, Joseph M ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

anabolic therapy; antiresorptive therapy; bisphosphonates drug holiday; bone strength; calcium; DEXA; fragility fracture; FRAX; secondary osteoporosis; vitamin D

Indexed keywords

ANABOLIC AGENT; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBAMAZEPINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; LOOP DIURETIC AGENT; METHOTREXATE; PARATHYROID HORMONE[1-34]; PHENYTOIN; PROTON PUMP INHIBITOR; THYROID HORMONE; VITAMIN D;

ANAMNESIS; BONE STRENGTH; BONE TURNOVER; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; HUMAN; LABORATORY DIAGNOSIS; OSTEOPOROSIS; PHYSICAL EXAMINATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; SURGEON; TREATMENT PLANNING;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MALE; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT;

EID: 80052265969     PISSN: 08905339     EISSN: 15312291     Source Type: Journal    
DOI: 10.1097/BOT.0b013e3181f9b389     Document Type: Review

References (87)

1. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721-739. (Pubitemid 30174026)
2. Wilkins K. Health care consequences of falls for seniors. Health Rep. 1999;10:47-55(ENG); 47-57(FRE).
3. Paksima N, Koval KJ, Aharanoff G, et al. Predictors of mortality after hip fracture: A 10-year prospective study. Bull NYU Hosp Jt Dis. 2008;66: 111-117. (Pubitemid 351898375)
4. Alegre-Lopez J, Cordero-Guevara J, Alonso-Valdivielso JL, et al. Factors associated with mortality and functional disability after hip fracture: An inception cohort study. Osteoporos Int. 2005;16:729-736. (Pubitemid 40933588)
5. Ensrud KE, Thompson DE, Cauley JA, et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc. 2000;48:241-249. (Pubitemid 30164205)
6. Dell RM, Greene D, Anderson D, et al. Osteoporosis disease management: What every orthopaedic surgeon should know. J Bone Joint Surg Am. 2009;91(Suppl 6):79-86.
7. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259. (Pubitemid 26147662)
8. Streeten EA, Mohamed A, Gandhi A, et al. The inpatient consultation approach to osteoporosis treatment in patients with a fracture. Is automatic consultation needed? J Bone Joint Surg Am. 2006;88:1968-1974. (Pubitemid 44352743)
9. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281-289. (Pubitemid 34219441)
10. Lochmuller EM, Zeller JB, Kaiser D, et al. Correlation of femoral and lumbar DXA and calcaneal ultrasound, measured in situ with intact soft tissues, with the in vitro failure loads of the proximal femur. Osteoporos Int. 1998;8:591-598. (Pubitemid 28566976)
11. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: Scientific review. JAMA. 2002;288:1889-1897. (Pubitemid 35168145)
12. Kanis JA, Oden A, Johansson H, et al. FRAX and its applications to clinical practice. Bone. 2009;44:734-743.
13. Dargent-Molina P, Piault S, Breart G, EPIDOS Study Group. A comparison of different screening strategies to identify elderly women at high risk of hip fracture: Results from the EPIDOS prospective study. Osteoporos Int. 2003;14:969-977. (Pubitemid 40824269)
14. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004; 164:1108-1112. (Pubitemid 38668990)
15. Felsenberg D, Boonen S. The bone quality framework: Determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther. 2005;27:1-11. (Pubitemid 40342573)
16. Boskey AL, DiCarlo E, Paschalis E, et al. Comparison of mineral quality and quantity in iliac crest biopsies from high-and low-turnover osteoporosis: An FT-IR microspectroscopic investigation. Osteoporos Int. 2005;16:2031-2038. (Pubitemid 41790924)
17. Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761-1768. (Pubitemid 27500187)
18. Kelman A, Lane NE. The management of secondary osteoporosis. Best Pract Res Clin Rheumatol. 2005;19:1021-1037. (Pubitemid 41748512)
19. Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002; 77:453-468. (Pubitemid 34465153)
20. Peris P, Guanabens N, Monegal A, et al. Aetiology and presenting symptoms in male osteoporosis. Br J Rheumatol. 1995;34:936-941.
21. Caplan GA, Scane AC, Francis RM. Pathogenesis of vertebral crush fractures in women. J R Soc Med. 1994;87:200-202. (Pubitemid 24124031)
22. Gaugris S, Heaney RP, Boonen S, et al. Vitamin D inadequacy among post-menopausal women: A systematic review. QJM. 2005;98:667-676. (Pubitemid 41236096)
23. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81:353-373. (Pubitemid 43334631)
24. Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005;90:3215-3224. (Pubitemid 41014278)
25. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281.
26. Natoli RM, Skaalure S, Bijlani S, et al. Intracellular Na(+) and Ca(2+) modulation increases the tensile properties of developing engineered articular cartilage. Arthritis Rheum. 2010;62:1097-1107.
27. Turner CH. Bone strength: Current concepts. Ann N Y Acad Sci. 2006; 1068:429-446. (Pubitemid 43824172)
28. Mankin HJ. Pathophysiology of Orthopaedic Diseases. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2006:123-129.
29. Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet. 2008;372:155-163. (Pubitemid 351952259)
30. Hodgson SF. Corticosteroid-induced osteoporosis. Endocrinol Metab Clin North Am. 1990;19:95-111. (Pubitemid 20142109)
31. Briot K, Roux C. Drug-induced osteoporosis: Beyond glucocorticoids. Curr Rheumatol Rep. 2008;10:102-109.
32. Rejnmark L, Vestergaard P, Heickendorff L, et al. Effects of long-term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover. J Intern Med. 2005;257:176-184. (Pubitemid 40193967)
33. Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in patients treated with loop diuretics. J Intern Med. 2006;259:117-124.
34. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83: 251-259.
35. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76-83. (Pubitemid 44306164)
36. Elliot-Gibson V, Bogoch ER, Jamal SA, et al. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: A systematic review. Osteoporos Int. 2004;15:767-778. (Pubitemid 39361946)
37. Hollis BW, Wagner CL. Normal serum vitamin D levels. N Engl J Med. 2005;352:515-516; author reply 515-516.
38. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: Implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 2005;135:317-322. (Pubitemid 40194499)
39. Heaney RP, Dowell MS, Hale CA, et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr. 2003;22:142-146. (Pubitemid 36417827)
40. Oh JH, Kim SH, Kim JH, et al. The level of vitamin D in the serum correlates with fatty degeneration of the muscles of the rotator cuff. J Bone Joint Surg Br. 2009;91:1587-1593.
41. Cranney A, Horsley T, O'Donnell S, et al. Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess (Full Rep). 2007;158:1-235.
42. Ruohola JP, Laaksi I, Ylikomi T, et al. Association between serum 25(OH)D concentrations and bone stress fractures in Finnish young men. J Bone Miner Res. 2006;21:1483-1488. (Pubitemid 44300055)
43. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003;9:544-564.
44. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241-1249. (Pubitemid 41094364)
45. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-661. (Pubitemid 34815869)
46. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348: 1535-1541. (Pubitemid 26411651)
47. Johnell O, Oden A, De Laet C, et al. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int. 2002;13: 523-526. (Pubitemid 34790623)
48. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
49. Unnanuntana A, Gladnick BP, Donnelly E, et al. The assessment of fracture risk. J Bone Joint Surg Am. 2010;92:743-753.
50. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: A meta-analysis. JAMA. 2004;291:1999-2006. (Pubitemid 38544282)
51. Christakos S, Dhawan P, Liu Y, et al. New insights into the mechanisms of vitamin D action. J Cell Biochem. 2003;88:695-705. (Pubitemid 36258819)
52. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged or =60 y. Am J Clin Nutr. 2004; 80:752-758. (Pubitemid 41115542)
53. Holick MF. Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging. 2007;24:1017-1029. (Pubitemid 350145410)
54. Heaney RP, Davies KM, Chen TC, et al. Human serum 25- hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77:204-210. (Pubitemid 36015393)
55. Tangpricha V, Koutkia P, Rieke SM, et al. Fortification of orange juice with vitamin D: A novel approach for enhancing vitamin D nutritional health. Am J Clin Nutr. 2003;77:1478-1483. (Pubitemid 39655283)
56. Feskanich D, Weber P, Willett WC, et al. Vitamin K intake and hip fractures in women: A prospective study. Am J Clin Nutr. 1999;69:74-79. (Pubitemid 29031254)
57. Tucker KL. Osteoporosis prevention and nutrition. Curr Osteoporos Rep. 2009;7:111-117.
58. Cobb TK, Gabrielsen TA, Campbell DC 2nd, et al. Cigarette smoking and nonunion after ankle arthrodesis. Foot Ankle Int. 1994;15:64-67. (Pubitemid 24069034)
59. Tucker KL, Jugdaohsingh R, Powell JJ, et al. Effects of beer, wine, and liquor intakes on bone mineral density in older men and women. Am J Clin Nutr. 2009;89:1188-1196.
60. Goodman SB, Jiranek W, Petrow E, et al. The effects of medications on bone. J Am Acad Orthop Surg. 2007;15:450-460.
61. Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2008;4: CD005088.
62. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356: 1809-1822. (Pubitemid 46698462)
63. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-340. (Pubitemid 32107641)
64. Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75:462-468. (Pubitemid 40174503)
65. Chapurlat RD, Palermo L, Ramsay P, et al. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int. 2005;16:842-848. (Pubitemid 40933602)
66. Tosteson AN, Burge RT, Marshall DA, et al. Therapies for treatment of osteoporosis in US women: Cost-effectiveness and budget impact considerations. Am J Manag Care. 2008;14:605-615.
67. Eriksen EF, Lyles KW, Colon-Emeric CS, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res. 2009;24:1308-1313.
68. Amanat N, McDonald M, Godfrey C, et al. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. 2007;22:867-876. (Pubitemid 351339747)
69. McDonald MM, Dulai S, Godfrey C, et al. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone. 2008;43: 653-662.
70. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17:897-907. (Pubitemid 43785797)
71. Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: A case control study. Osteoporos Int. 2009;20:1353-1362.
72. Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22: 346-350. (Pubitemid 351630250)
73. Goddard MS, Reid KR, Johnston JC, et al. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics. 2009;32:10.3928/01477447- 20090624-27.
74. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555-1565.
75. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441. (Pubitemid 32402100)
76. Alkhiary YM, Gerstenfeld LC, Krall E, et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am. 2005;87:731-741. (Pubitemid 40489347)
77. Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res. 1999;14:960-968. (Pubitemid 29262891)
78. Aspenberg P, Johansson T. Teriparatide improves early callus formation in distal radial fractures. Acta Orthop. 2010;81:236-238.
79. Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008;23:1591-1600.
80. Lewiecki EM. Denosumab update. Curr Opin Rheumatol. 2009;21: 369-373.
81. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26:4875-4882.
82. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745-755.
83. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357:905-916.
84. Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets. 2009;13:485-496.
85. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24:578-588.
86. Yaccoby S, Ling W, Zhan F, et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109:2106-2111. (Pubitemid 46348212)
87. Yadav VK, Balaji S, Suresh PS, et al. Pharmacological inhibition of gutderived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med. 2010;16:308-312.